丝裂霉素C、长春地辛和美法仑联合化疗治疗难治性转移性乳腺癌。
Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer.
作者信息
Rausa L, Russo A, Gebbia V, Gebbia N, D'Alessandro N, Palmeri S
机构信息
Section of Clinical Oncology, University of Palermo, Italy.
出版信息
J Cancer Res Clin Oncol. 1991;117(3):266-8. doi: 10.1007/BF01625437.
A combination of mitomycin C, vindesine and melphalan was administered to 33 patients with heavily pretreated refractory breast cancer. The overall response rate was 27% with a mean duration of more than 10.2 months. A stabilization with a mean duration of 5.1 months was seen in 56% of cases, while 20% of patients progressed. Gastrointestinal toxicity, mostly grade 1 or 2 nausea/vomiting was seen in 85% of cases, grade 1 or 2 leukopenia in 60% of patients, and grade 1 or 2 thrombocytopenia in 42%. Considering the good compliance of this regimen and the poor prognosis of patients with refractory advanced breast cancer, this combination can be useful as a palliative treatment of breast carcinoma.
对33例经过多次治疗的难治性乳腺癌患者使用丝裂霉素C、长春地辛和美法仑联合治疗。总缓解率为27%，平均缓解持续时间超过10.2个月。56%的病例病情稳定，平均稳定持续时间为5.1个月，而20%的患者病情进展。85%的病例出现胃肠道毒性，大多为1级或2级恶心/呕吐，60%的患者出现1级或2级白细胞减少，42%的患者出现1级或2级血小板减少。鉴于该方案的良好耐受性以及难治性晚期乳腺癌患者的预后较差，这种联合治疗可作为乳腺癌姑息治疗的一种有效方法。
Zotero 插件